Analysis – Page 9 – Goldea Capital

KOIL Energy Reports Third Quarter 2025 Results

Written by Customer Service on November 14, 2025. Posted in Earnings Releases And Operating Results.

– Revenue of $6.4 million, 22% growth – Gross margin of 32% – Adjusted EBITDA margin of -3% due to a write-off – Successful entry into renewables – First Contracts in Brazil HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its third quarter 2025 results. “We increased revenue by 22% this quarter; KOIL Energy is growing again,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “During the quarter KOIL Energy generated revenues of $6.4 million. These are clear indicators of strengthening demand both within services and products.” Third Quarter 2025 Results: For the three months ending September 30, 2025, Koil Energy generated revenues...

Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on November 14, 2025. Posted in Earnings Releases And Operating Results.

GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We continue to achieve meaningful milestones on our path toward U.S. Food and Drug Administration (FDA) approval and eventual commercialization of AD04, our lead investigational drug, a serotonin-3 receptor antagonist being developed for the treatment of Alcohol Use Disorder (AUD). A key highlight of our recent progress was the successful End of Phase 2 (EOP2) meeting with the FDA, where we received valuable guidance...

SEALSQ Launches U.S.-Based Post-Quantum Root of Trust to Deliver Quantum-Resistant PKI and Device Identity Services as part of the Made In USA strategy

Written by Customer Service on November 14, 2025. Posted in Public Companies.

Geneva, Switzerland, Nov. 14, 2025 (GLOBE NEWSWIRE) — Video Link: https://youtu.be/s4YihS22og0?si=3jBD6XJ-uoKY1Jom SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), a leader in post-quantum semiconductors, PKI, and secure hardware solutions, today announced the upcoming launch of a U.S.-based Post-Quantum Root of Trust, set to go live on Friday, November 21, 2025. This sovereign infrastructure is designed to enable American enterprises and government agencies to issue, manage, and validate quantum-resistant digital identities and PKI services entirely on U.S. soil. The new platform aims to bolsters national cybersecurity and digital sovereignty by delivering locally controlled, quantum-secure certificate issuance, lifecycle management, and hardware-anchored device provisioning for IoT, industrial control systems, telecommunications, and...

Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

Written by Customer Service on November 14, 2025. Posted in Public Companies.

IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook Cantor Notes PRE’s ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company’s Financial Position Cantor Forecasts $217 Million in FY2026 Revenue as IM8 Expands Internationally and Sharpens Strategic Focus CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that Cantor Fitzgerald has reiterated its Overweight rating on the Company in its latest equity research report dated November 11, 2025, while updating its 12-month price target to $31, compared to its prior target of $32. Cantor noted that this adjustment reflects valuation...

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY (a public company incorporated with limited liability in Ireland) WISDOMTREE SILVER 3X DAILY SHORT SECURITIES ISIN: IE00B8JG1787

Written by Customer Service on November 14, 2025. Posted in Public Companies.

14 November 2025 LEI: 2138003QW2ZAYZODBU23 LSE Code: 3SIS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE SILVER 3X DAILY SHORT SECURITIESISIN: IE00B8JG1787 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES ADJOURNMENT OF MEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser. If you have sold or transferred all of your WisdomTree Silver 3x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee...

Troilus Closes $172.5 Million Bought Deal Public Offering Including the Full Exercise of Over-Allotment Option

Written by Customer Service on November 14, 2025. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, Nov. 14, 2025 (GLOBE NEWSWIRE) — Troilus Gold Corp. (“Troilus” or the “Company”, TSX: TLG, OTCQX: CHXMF; FSE: CM5R) is pleased to announce that it has closed its previously announced bought deal public offering, including exercise of the over allotment option in full (the “Offering”). Pursuant to the Offering, the Company has issued 133,722,000 common shares of the Company (the “Offered Shares”), at a price of $1.29 per Common Share for aggregate gross proceeds of $172,501,380. The Offering was completed through a syndicate of underwriters co-led by Desjardins Capital Markets, Cormark Securities Inc., and Haywood Securities Inc. and including BMO Nesbitt Burns Inc., Red Cloud Securities Inc. and Velocity Trade Capital Ltd. The...

SPAR Group, Inc. Reports Third Quarter 2025 Results

Written by Customer Service on November 14, 2025. Posted in Earnings Releases And Operating Results.

Executing Strategy to Create a Structurally Leaner, Profitable Business CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR,” “SPAR Group” or the “Company”), an innovative services company offering comprehensive merchandising, marketing, and distribution solutions to retailers and brands throughout the United States and Canada, today reported financial and operating results for the three and nine months ended September 30, 2025. William Linnane, President and Chief Executive Officer of SPAR Group, commented, “Although we are very pleased to report topline momentum this quarter, with combined U.S. and Canada net revenues up 28.2% over third quarter last year, we recognize that there is more work ahead to build a structurally leaner and more profitable business. The quarter had a benefit to its...

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Written by Customer Service on November 14, 2025. Posted in Earnings Releases And Operating Results.

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. “The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—all supporting belapectin’s durable antifibrotic activity and potential to slow disease progression in patients with compensated MASH cirrhosis. We submitted the NAVIGATE data package to the FDA and requested feedback on proposed next steps, with guidance anticipated by year-end. As we move forward, our focus remains on advancing dialogue with...

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Written by Customer Service on November 14, 2025. Posted in Earnings Releases And Operating Results.

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued best-in-disease durability and tolerability in BOND-003 Cohort C with robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with HR NMIBC unresponsive to Bacillus Calmette Guerin (BCG) Completed enrollment of PIVOT-006, one of the largest randomized Phase 3 studies in intermediate risk (IR) NMIBC encompassing broadest range of patients per AUA/SUO Guidelines Well-positioned to deliver on key milestones with $680.3 million cash and cash equivalents and marketable securities sufficient to fund operations into the first half of 2028IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE)...

APWC Announces Financial Results for the Third Quarter of 2025

Written by Customer Service on November 14, 2025. Posted in Earnings Releases And Operating Results.

Quarterly revenue of $128.4 million, up 1% from Q2 and up 5% from a year ago Quarterly operating profit of $3.8 million, up 19% from Q3 2024TAIPEI, Taiwan, Nov. 14, 2025 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (“APWC” or the “Company”) (NASDAQ: APWC) today reported unaudited results for the third quarter ended September 30, 2025. Quarterly revenue was $128.4 million, up 1% from the previous quarter and up 5% from a year ago. Copper unit volume, measured by the tonnage of copper contained in the wire and cable sold, increased 2% in the third quarter from Q2 and increased 12% from a year ago. This does not include other raw materials, such as aluminum and insulation materials. For the quarter, earnings per share were $0.05, up 67% from the previous quarter and down 17% from...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals